IGF-1 LR3

What Is IGF-1 LR3?

IGF-1 LR3 is a laboratory-modified version of insulin-like growth factor 1 (IGF-1), a hormone the body naturally produces, largely in response to growth hormone, that plays a central role in cell growth and metabolism. The modification involves two changes: an amino acid substitution near the start of the chain and an added 13-amino acid extension, together referred to as the "Long R3" modification.^[1]

These changes were originally designed to solve a specific research problem. Natural IGF-1 binds tightly to a family of carrier proteins in the blood called IGF binding proteins, which limits how much of it is actually available to interact with cells. The LR3 modification sharply reduces that binding, leaving more of the molecule freely available, which is why researchers use it as a tool to study sustained IGF-1 receptor activity.

What IGF-1 LR3 Is Being Researched For

• Growth Signaling

  The original research on IGF-1 LR3 examined how reducing its binding to carrier proteins affected organ growth and circulating hormone levels in animal models.^[2]

• Metabolic and Hormonal Feedback

  Animal studies have also looked at how sustained IGF-1 LR3 exposure affects the body's own hormone production, including growth hormone and native IGF-1 levels, since the body's feedback systems respond to how much IGF-1 signaling is already present.^[3]

• Cell Growth and Protein Synthesis Research

  Beyond whole-animal studies, IGF-1 LR3 is used in cell-based research to study the signaling pathways activated when IGF-1 receptors are engaged for extended periods.

How IGF-1 LR3 Works

• Escaping the Body's Natural Regulation System

  Research points to the LR3 modification dramatically reducing IGF-1 LR3's affinity for IGF binding proteins, the carrier proteins that normally hold most circulating IGF-1 in reserve. With less of it bound up, more stays available to interact directly with cells.^[1]

• Activating Growth-Related Cell Signaling

  Research points to IGF-1 LR3 binding to the same receptor as native IGF-1, triggering internal signaling pathways involved in cell growth and protein production. Because it stays active longer than the natural hormone, researchers use it to study what happens when that signaling is sustained rather than brief.

Reconstitution and Handling

IGF-1 LR3 is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water, sterile water, or a dilute acidic buffer before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

IGF-1 LR3 was originally engineered as a research tool to get around the body's own regulation of IGF-1 activity, and that remains its core research value: letting scientists study what happens when IGF-1 signaling stays active longer than it naturally would. Its research base spans early animal studies on growth and hormonal feedback through to ongoing cell-level signaling research. As with several compounds on this site, no published human trial data exists yet.

Frequently Asked Questions

Sources and Research

1. Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213-223.
2. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-253.
3. Dunaiski V, Dunshea FR, Walton PE, Goddard C. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. J Endocrinol. 1997;155(3):559-565.